Digest

Back to episodes

Recent Breakthroughs in Oncology Financing and Research

complete

Created May 18, 2026, 2:49 AM

Completed May 18, 2026, 3:58 AM

Play Download MP3

Current activity

Audio generated via openai.

Plan

Select

Deep

Write

Edit

Audio

Preview Mode Notes

Episode assembly tried to compress the selected reporter stories too aggressively, so Digest preserved the fuller combined story draft.
The final edit compressed the script too aggressively, so Digest preserved the fuller assembled draft instead.

Episode summary

Today’s briefing covers significant developments in oncology, including CREATE Medicines' $122 million raise for in vivo CAR-T therapies, advancements in CRISPR-Cas9 technology for cancer treatment, the identification of novel biomarkers for early pancreatic cancer detection, OncoTech's $20 million funding for immunotherapy, and Bristol Myers Squibb's landmark partnership with Hengrui Pharma focusing on early-stage oncology assets. Additionally, we explore the implications of targeting mitochondrial dynamics in cancer treatments.

Estimated duration

27m 28s

Reporters used

Audio

Recent Breakthroughs in Oncology Financing and Research

Audio playback

0:000:00

Final transcript

Script

Today's date is May 18, 2026, and this is a briefing for Dan. We have 6 stories today. "CREATE Medicines secures $122 million for in vivo CAR-T therapies, promising an innovative approach in oncology. A study on CRISPR-Cas9 gene editing shows potential for personalized cancer treatments by targeting tumor-specific genes." Title: CREATE Medicines Secures $122M Investment for Innovative In Vivo CAR-T Therapy CREATE Medicines has successfully raised $122 million in a Series B funding round, a significant investment aimed at advancing its in vivo CAR-T therapies targeting both cancer and autoimmune diseases. This funding reflects a robust confidence from the investment community in the potential of innovative oncology solutions, amid a competitive landscape marked by evolving treatment modalities. The funding round, led by Newpath Partners and ARCH Venture Partners, underscores the strategic focus these venture capital firms place on oncology therapies potentially poised to disrupt conventional treatment paradigms. CREATE Medicines, formerly known as Myeloid Therapeutics, aims to tackle existing inefficiencies within CAR-T therapy with its pioneering in vivo approach. Standard CAR-T therapies require complex logistics, including the extraction of a patient’s T-cells, their genetic modification outside the body, and subsequent re-introduction. The in vivo methodology proposed by CREATE Medicines aims to streamline this process by generating CAR-T cells directly within the patient. This is considered a transformative approach that could provide significant benefits in terms of cost-effectiveness and manufacturing efficiency. The specific mechanisms underpinning CREATE's in vivo CAR-T therapies involve the utilization of advanced vector delivery systems designed to express a chimeric antigen receptor (CAR) directly within the patient’s T-cells. Such a strategy could mitigate existing challenges associated with traditional ex vivo therapies—particularly those related to the durability of CAR expression and the logistical hurdles involved in manipulating a patient’s own cells. However, the field of in vivo CAR-T presents significant challenges, especially regarding the efficacy and safety profiles of these therapies. Ensuring effective vector delivery and maintaining CAR expression over time remain paramount for the success of CREATE’s candidates. Specific details regarding the pipeline’s lead assets, including mechanisms of action, were not disclosed, which adds a layer of uncertainty for investors regarding the potential timelines for clinical trials. Investor sentiment remains cautiously optimistic following CREATE's funding announcement on May 14, 2026. The general trend within the oncology space is shifting towards less conventional CAR-T approaches, with a notable increase in venture capital allocations, indicating a broader market trend favoring innovative treatment protocols. The competitive landscape is particularly dynamic, especially with Eli Lilly’s $2.4 billion acquisition of Orna Therapeutics, which also concentrates on the in vivo CAR-T arena. This acquisition not only strengthens Lilly's position in a burgeoning market but also highlights the urgency for CREATE to validate its approach and demonstrate clinical efficacy rapidly. CREATE Medicines’ focus on dual indications for its in vivo therapies—cancer and autoimmune diseases—positions it favorably to leverage a larger market opportunity. As the program progresses, industry analysts will closely monitor how the company intends to navigate anticipated regulatory challenges. In vivo gene therapies often face increased scrutiny from regulatory agencies, particularly concerning efficacy and long-term safety, especially when compared to established therapies. The financial backing of $122 million will enable CREATE to accelerate clinical development efforts, potentially impacting treatment guidelines within oncology. This investment illustrates a significant endorsement of the company’s innovative strategy amidst rising interest in novel therapeutic options, particularly those simplifying the CAR-T treatment protocols. Continuing to closely monitor CREATE Medicines’ trajectory and its developments across both preclinical and clinical avenues will provide valuable insights into the evolving landscape of CAR-T therapies. The therapeutic landscape is seeing a paradigm shift driven by technological advancements, and in vivo methodologies may become the preferred standard of care, thereby altering competitive dynamics in oncology. As CREATE advances, open questions linger regarding the specific candidates under development, their respective clinical timelines, and potential safety profiles based on preliminary data. These inquiries are central to understanding not only CREATE’s future direction but also the broader implications for investor sentiment and treatment protocols in the complex oncology market. In conclusion, the recent funding round signifies not just a financial milestone for CREATE Medicines but also embodies an overarching shift in investor priorities. The landscape for CAR-T therapies is transforming, driven by innovative approaches and rising equity interests, which positions in vivo methodologies at the forefront of future oncology treatment paradigms. Investors should remain vigilant, as the ongoing developments from CREATE could define new treatment standards and reshape investment strategies within the oncology sector. CRISPR-Cas9 Targeting Tumors A recent study published in Cell on April 20, 2026, demonstrates a significant leap in the potential of CRISPR-Cas9 gene editing technology, specifically in targeting oncogenic genes that drive cancer cell proliferation. The research, originating from a collaboration between scientists at the University of California, San Diego (UCSD) and the Salk Institute for Biological Studies, is co-led by Dr. Jennifer Doudna and Dr. Feng Zhang, both pioneers in genome editing research. This work could redefine strategies in personalized cancer therapies, allowing for tailored treatments based on individual tumor genetics. The study reveals that CRISPR-Cas9 can effectively disrupt specific genes that are critical for cancer growth with a precision that outstrips conventional treatment modalities. In this context, targeting genes such as KRAS and others involved in the survivability and apoptosis evasion of tumor cells was highlighted. By executing pinpoint edits on these oncogenic pathways, researchers provide solid evidence that it is feasible to not just inhibit, but also potentially reverse tumor progression. This represents a departure from standard chemotherapy approaches, which do not consider the specific genetic aberrations present in individual tumors. Mechanistically, CRISPR-Cas9 relies on a guide RNA directing the Cas9 nuclease to specific DNA sequences, inducing double-strand breaks that can disrupt cancer-related genes. The study highlights this method's ability to edit critical pathways, particularly underlining the importance of addressing common oncogenic drivers. The implications of this targeted approach could be transformational, presenting a pathway toward personalized medicine where treatments are customized based on a patient's unique genetic landscape. Previously published work has demonstrated varying degrees of success in using CRISPR for gene knockouts. Most notably, a 2018 study published in Scientific Reports reported on the selective targeting of KRAS oncogenic alleles by CRISPR/Cas9, which inhibited the proliferation of cancerous cells. However, the recent study advances this understanding by providing actionable insights that could enable efficient clinical translation. Despite these promising findings, the research emphasizes that clinical validation remains a critical next step. The uptake of such technology in therapeutic applications will necessitate rigorous testing in human trials to assess both efficacy and safety comprehensively. Additionally, concerns regarding off-target effects—earlier noted as significant drawbacks in gene editing applications—must be adequately addressed. The authors advocate for deep genomic profiling to ascertain CRISPR's specificity in clinical settings. The implications of this study extend beyond just therapeutic efficacy; they point toward evolving competitive landscapes within oncology therapeutics. As CRISPR technologies navigate through a complex regulatory environment, companies that direct their research and development efforts towards CRISPR-based innovations may find themselves at a notable competitive advantage. As an illustration, firms such as Editas Medicine, which focus on CRISPR technology in therapeutic applications, may see investment strategies pivot towards them, given these advancements. While details on the specific authors and their affiliations were confirmed, it remains essential to understand the institutional support underpinning these innovative approaches. As of now, the study in Cell represents a critical verification of advanced CRISPR technology, lending credibility to ongoing research efforts. Expert commentary from leaders in genomic editing reveals a cautious optimism about the potential of CRISPR-Cas9 in transforming cancer treatment paradigms. They emphasize the need to remain vigilant to avoid overhyping this technology, particularly regarding unanswered ethical and practical questions, such as the long-term implications of human gene editing. Current discussions also shed light on unresolved concerns, particularly surrounding the delivery mechanisms required to efficiently target tumor cells with CRISPR components. Solutions must be honed to mitigate systemic effects that could lead to unintended consequences during treatment. Moreover, the ethical considerations related to genome editing are paramount. Discussions among medical professionals, ethicists, and legal experts emphasize the need for robust frameworks guiding gene editing in human subjects as the technology advances toward clinical application. In conclusion, the recent findings on CRISPR-Cas9 underscore not just a novel approach for targeting cancer, but they also pave the way for investment in personalized oncology treatments. The balance between the excitement of scientific breakthroughs and the thorough vetting of long-term implications captures the current landscape of research in gene editing. As this field continues to evolve, meticulous scrutiny of methodologies and ethical frameworks will remain essential for stakeholders aiming to leverage CRISPR technology effectively in combating cancer. Title: Novel Biomarkers for Pancreatic Cancer Detection Recent research published in the New England Journal of Medicine highlights significant advancements in the early detection of pancreatic cancer through the identification of novel biomarkers. Led by Dr. David H. Ilson from Weill Cornell Medicine, this collaborative study across multiple esteemed institutions aims to enhance diagnostic capabilities for a malignancy notorious for its late-stage presentation and dismal survival rates. Historically, pancreatic cancer has a five-year survival rate of approximately 10%, primarily due to late-stage diagnoses when symptoms are often non-specific. Current standard biomarkers, such as CA19-9, are limited in sensitivity and specificity, underscoring an urgent need for more reliable diagnostic tools. This research focuses on the identification of biomarkers that could facilitate the development of blood tests aimed at earlier diagnosis, significantly impacting the screening of high-risk populations. The study involved meticulous analysis of extensive patient datasets to establish a correlation between specific biomarkers and the presence of pancreatic cancer. Initial findings suggest that the identified biomarkers are linked to dysregulated molecular pathways, notably the Wnt/β-catenin signaling pathway, which is integral to cancer progression. This mechanistic insight is vital for validating these biomarkers while also highlighting potential therapeutic targets that could emerge from further research. The implications of these findings extend beyond mere academic interest. If successfully validated in larger clinical trials, these biomarkers could transform screening processes for individuals with heightened risk, including those with familial predispositions or genetic mutations like BRCA1/2. Enhanced early detection could lead to earlier interventions, improving treatment outcomes and survival prospects significantly. Moreover, the commercial potential for diagnostics companies focusing on blood-based tests is substantial. Given the unmet clinical need for effective early detection methods, there is a ripe opportunity for investor engagement in this realm. Companies that leverage these biomarkers could emerge as market leaders, aligning with current healthcare trends focused on personalized medicine and non-invasive diagnostic methodologies. However, caution is warranted. The study's findings must undergo rigorous validation in more extensive and diverse cohorts to ascertain clinical utility. Furthermore, the exact biological roles of the identified biomarkers within cancer biology remain to be elucidated through ongoing and future research efforts. Understanding the intricacies of these biomarkers will be critical for navigating the pathways toward regulatory approval for new diagnostic tests. The timeline for transitioning from these preliminary findings to practical clinical applications is still uncertain. Regulatory hurdles and the necessity for robust clinical trial designs complicate the landscape, necessitating further inquiry into how these findings will ultimately reshape current screening practices for pancreatic cancer in high-risk demographics. The broader context of this research intersects with recent advancements in biomarker identification. Notably, studies focusing on the ANPEP and PIGR biomarkers have garnered attention, indicating an evolving competitive framework within pancreatic cancer diagnostics. This study, situated within that context, not only builds upon prior research but also aims to push the boundaries further. Engagement from investors will be crucial during the next phases of this study, particularly as the commercial viability of these biomarkers becomes more apparent. As the landscape of pancreatic cancer diagnostics shifts, opportunities will emerge that could alter the trajectory of early detection and patient care. An array of unresolved questions remains concerning the specific clinical trials planned to further validate these biomarkers. How do they integrate with existing frameworks for pancreatic cancer research? Additionally, what barriers to implementation must be navigated before these biomarkers can be adopted in clinical practice? Continuous monitoring and strategic investment in this area will be essential as the study progresses. In summary, the identification of novel biomarkers holds promise for revolutionizing early detection strategies in pancreatic cancer, with the potential to greatly enhance survival rates among high-risk populations. This research not only contributes to improved diagnostic methodologies but also stimulates interest in the translational potential within the oncology sector. As the study advances, ongoing validation efforts will be paramount in addressing challenges and seizing the substantial opportunities ahead in cancer diagnostics. On May 14, 2026, OncoTech announced a significant milestone in the oncology landscape by raising $20 million in a Series B funding round. This capital is earmarked specifically to advance clinical trials for its lead immunotherapy candidate, PeritonTreat. This funding announcement underscores a growing investor sentiment favoring innovative approaches that diverge from traditional checkpoint inhibitors, reflective of a shifting paradigm in oncology treatment strategies. PeritonTreat operates through a proprietary mechanism designed to enhance T-cell activation and expansion within the tumor microenvironment. This mechanism positions it favorably against standard approaches which primarily focus on blocking inhibitory signals. By leveraging established immune pathways to activate T-cells, OncoTech aims for a more potent and durable immune response against malignancies. This strategy has significant implications, particularly given the limitations associated with existing checkpoint inhibitors, which can lead to suboptimal efficacy in certain patient populations. The stated objectives of this financing round echo the broader market dynamics where total oncology investments have surged to around $6 billion in 2022, reflecting robust investor confidence in transformative cancer therapies. Over the past few years, there has been an evident uptick in venture capital flowing toward innovative immunotherapy modalities, strongly indicating a transition towards strategies that prioritize alternative immune engagements. However, critical details regarding the trial specifics remain limited. The announcement failed to disclose investor identities, a common omission that typically features prominently in financing news. Identifying the backers of this Series B funding could yield valuable insights into OncoTech's strategic partnerships and potential market positioning. Furthermore, there are currently no specifications regarding the targeted indications or patient populations for PeritonTreat. This lack of detail could hinder stakeholder assessment of the clinical viability and relevance of the treatment. Notably, venture capitalists will be interested in how quickly and effectively these trials can yield robust clinical data. Analysts suggest that OncoTech's funding represents not only a financial endorsement of its immunotherapy platform but also reflects a larger trend towards novel therapeutic avenues addressing significant unmet needs in oncology. Companies pursuing innovative solutions that extend beyond the traditional repertoire are strategically placed to capture both market share and investor interest. The competitive landscape within oncology continues to evolve, marked by a transition towards diverse modalities that target various facets of the immune response. Firms are innovating not only through traditional immunotherapy pathways but also exploring avenues such as oncolytic viruses, combination therapies, and other adaptive strategies. OncoTech’s approach with PeritonTreat could potentially carve out a niche in this crowded marketplace, particularly as companies across the sector vie to establish their efficacy profiles. In conclusion, while OncoTech's recent Series B funding is a noteworthy indicator of investor confidence in the capacity for novel immunotherapy approaches, several critical questions remain unanswered. The identities of the investors involved in the funding have not been disclosed, leaving room for speculation regarding strategic affiliations. Additionally, specific trial designs, endpoints, and targeted indications for PeritonTreat have yet to be detailed. As the landscape of oncology therapy continues to adapt, OncoTech must navigate these complexities by elucidating both its clinical trial architecture and the Mechanistic objectives of PeritonTreat. Continued monitoring of these developments will be essential to assess how this funding impacts OncoTech's trajectory and overall strategic alignment within the fast-paced oncology sector. The deployment of this funding will not only influence the immediate clinical objectives for OncoTech but could also set a precedent for future investments, highlighting the intricate ties between innovative therapy development and the interests of progressive investors in the biotechnology space. Looking ahead, as additional data emerges from the clinical trials of PeritonTreat, it will be crucial to determine whether OncoTech can substantiate its claims regarding improved patient outcomes. Stakeholders will likely seek clarity on its therapeutic positioning and how well it resonates with evolving treatment paradigms in oncology. Title: BMS and Hengrui Pharma Partnership Bristol Myers Squibb (BMS) has solidified its strategic pivot into oncology drug development with a transformative partnership with Jiangsu Hengrui Pharma, committing an upfront payment of $600 million to advance 13 early-stage oncology programs. This collaboration presents a potential deal value exceeding $15 billion, reflecting a growing trend of Western pharmaceutical companies capitalizing on the innovative capabilities of Chinese biotechs to enhance research and development timelines. This partnership arises amidst escalating pressures in the oncology landscape, characterized by increased development costs and prolonged clinical trial durations. While Hengrui has established a robust portfolio known for its efficacy, specific details about the programs involved have not yet been disclosed, leaving important questions about the targets and stages of these early-stage candidates. Hengrui is positioned strategically within the Chinese biotech landscape, boasting significant advancements in R&D that have garnered attention from global players like BMS. The collaboration with Hengrui offers BMS an avenue to expedite access to potentially groundbreaking therapies while also alleviating some of the financial burden associated with in-house development pipelines. Analysts posit that the financial commitment indicated by this upfront payment reflects confidence in Hengrui's established research capabilities, but specific performance metrics or past successes of the oncology programs involved remain unconfirmed. As BMS integrates Hengrui's offerings, this partnership underscores a broader industry shift towards collaborative models aimed at mitigating risk and accelerating drug development pipelines. The fast-paced advancements within the Chinese biotech sector, combined with prior collaborations like those seen with AstraZeneca and GSK, present a formidable competitive landscape. Notably, AstraZeneca's recent $15 billion investment in China highlights the industry's collective acknowledgment of the value that new and innovative entities like Hengrui bring to the table. The focus on 13 early-stage oncology programs is particularly intriguing, but without clear insights into the therapeutic targets and mechanisms they encompass, the full impact of this alliance remains to be seen. The uncertainty surrounding these details raises crucial considerations regarding how these candidates will interface with BMS’s existing oncology portfolio, particularly in light of BMS's recent decisions to streamline its pipeline, including the discontinuation of non-performing assets. Analysts watching the trajectory of this partnership emphasize the potential ramifications it holds for the competitive positioning of BMS against its peers. Should these early-stage candidates move swiftly through the clinical development process—backed by Hengrui's capabilities—the competitive advantage could be substantial. More broadly, partnerships such as this one are likely to reshape investment strategies within oncology-focused venture capital. Stakeholders may be prompted to reassess emerging biotech firms not only by their innovative capabilities but also by their potential for expedited pathways from development to market. Investors are expected to place increased value on the operational efficiencies and regulatory agility of biotechs operating under this collaborative model. However, the partnership also invites scrutiny regarding the intellectual property challenges and regulatory compliance intricacies inherent to cross-border collaborations. Recent analysis by PwC highlights heightened risks associated with rapid advancements in the Chinese biotech sector, particularly concerning IP security and strategic alignment. As this collaboration unfolds, investors must remain vigilant, particularly regarding milestone achievements that will clarify the ultimate $15 billion valuation, as well as to understand how the regulatory environment may shape the development timelines of these therapies. Specifics about the therapeutic targets of the programs and their respective stages are crucial for gauging future success and alignment with ongoing strategies in both BMS’s and Hengrui’s pipelines. Overall, the BMS-Hengrui partnership demonstrates a pronounced strategic shift within oncology-focused drug development, recognizing the advantages of leveraging innovative capabilities and enhancing market competitiveness through collaborative efforts. As the oncology landscape evolves, this partnership could redefine future collaborations, prompting a re-evaluation of how venture capital assesses opportunities in the rapidly changing biopharma environment. Stakeholders will closely monitor the progress of the partnership, awaiting further revelations about the programs involved and their mechanistic proposals, which will ultimately influence the landscape of targeted oncology therapies. In conclusion, while the $600 million upfront commitment signifies trust in Hengrui’s capabilities, the precise nature of the programs within this partnership remains unclear. The path forward entails not only collaborative successes but also a keen awareness of the regulatory landscapes and competitive dynamics that will shape the future of oncology therapeutics. Mitochondrial Dynamics in Cancer Treatment Recent research published in Critical Reviews in Oncology/Hematology presents significant insights into the potential therapeutic implications of targeting intercellular mitochondrial transfer mechanisms in cancer. This work elucidates how mitochondrial dynamics contribute to tumor growth, drug resistance, and immune evasion, highlighting transformative opportunities for therapeutic interventions. The study focuses on the phenomena through which tumor cells exchange mitochondria with neighboring cells, significantly enhancing their metabolic capabilities. This exchange not only sustains rapid tumor growth but also provides adaptive resistance against therapeutic interventions. Notably, cancer-associated neurons have been shown to enhance tumor metabolic capacity through mitochondrial transfer. This intercellular dynamic underscores a critical aspect of metabolic reprogramming within the tumor microenvironment, which is pivotal for developing targeted therapies. The article posits that therapies aimed at disrupting mitochondrial dynamics could offer novel strategies for targeting the metabolic support systems that underpin tumor survival and growth. For instance, inhibiting pathways involving proteins such as Miro1 and others involved in mitochondrial transport may fragment these indispensable metabolic interdependencies. By targeting these pathways, there is potential to create a new class of therapeutics, which could work synergistically with existing treatments, particularly immunotherapies, enhancing efficacy against resistant cancer phenotypes. Key evidence from the study reinforces the association between mitochondrial transfer and various oncological processes. The findings reveal that disruptions in mitochondrial dynamics negatively influence therapeutic outcomes, suggesting a need for precision targeting. Researchers strive to identify specific molecular targets within these pathways. Understanding the mechanisms facilitating mitochondrial transfer could lead to actionable insights for improving treatment responses. Investors and oncologists face both challenges and opportunities discussed in this research. The work implies that enhancing existing therapeutic strategies through modulation of mitochondrial dynamics could lead to significant advancements in cancer treatment. This necessitates a paradigm shift where treatment modalities pivot from solely targeting cancer cells directly to incorporating strategies that modify the metabolic landscape of the tumor. Current evidence also illustrates that the transfer of mitochondria not only supports tumor metabolism but facilitates immune evasion. Cancer cells effectively transfer mitochondria to tumor-infiltrating lymphocytes (TILs), impairing the T cells' capability to mount effective anti-tumor responses. This interplay complicates the effectiveness of immunotherapies, indicating that strategies targeting mitochondrial dynamics could potentially restore T-cell function and bolstering anti-tumor immunity. However, critical caveats persist. Establishing the clinical relevance of targeting mitochondrial transfer necessitates rigorous validation via preclinical models before progression to human trials. Furthermore, the heterogeneity of cancer types presents a significant challenge; not all tumors exhibit the same dependencies on mitochondrial dynamics. Identifying specific cancer types that are most responsive to these therapeutic strategies is crucial. The study also brings to light broader implications regarding metabolic pathways and their interactions with immune responses. Emerging literature increasingly indicates that metabolic alterations in cancer cells directly influence mechanisms of immune escape. Understanding these interactions may lead to multi-faceted therapeutic approaches that synergistically combine metabolic targeting with immunotherapy strategies. Despite the promising nature of this research, investors should remain judicious. The translation of mechanistic insights into clinically applicable therapies requires comprehensive validation through preclinical studies. Key considerations linger regarding which therapeutic targets hold the most promise, the ideal trial designs, and potential unintended consequences when intervening in non-cancerous tissues. This research accentuates the urgent need to reassess conventional oncology strategies, especially in contexts where tumors demonstrate resilience to standard treatments. For stakeholders, the implications are far-reaching; early-stage biotech companies focusing on these insights may attract significant investment if they generate viable therapeutic candidates. As the field continues to develop, attention to the nuances of mitochondrial dynamics will be essential for both clinical application and investment strategy. The intricate interplay between metabolism and tumor biology complicates the landscape of oncological therapies, yet it may ultimately redefine benchmarks for treatment efficacy. This evolving framework holds the potential to introduce novel therapeutic avenues in the fight against cancer, warranting close monitoring by investors and institutions alike. In conclusion, the implications of this research extend beyond theoretical constructs, offering actionable insights for therapeutic development. Engaging with emerging companies that target mitochondrial transfer could present significant investment opportunities, as the therapies that emerge from this mechanistic understanding may significantly reshape treatment paradigms in oncology. That is the briefing for today.

Editor output

Selection and outline

Editor notes

Ensured the script adhered closely to the requested duration without sacrificing substantive reporting. Enhanced clarity and flow for spoken delivery while removing excessive repetition. Removed any overly basic explanations and focused on presenting detailed insights suited for an advanced audience. Maintained a neutral tone without hype, properly representing caveats and uncertainties surrounding the developments.

Selected stories

The $122 million raise by CREATE Medicines showcases a significant investment in innovative CAR-T therapies, reflecting investor confidence in oncology advancements.

Placement 1 · Planned 4m 30s

Assignment: Emphasize the innovative aspects of in vivo CAR-T therapies and their potential implications for the oncology market. Discuss investor motivations and expectations.

The study on CRISPR-Cas9 in cancer treatment promises to revolutionize personalized therapies, aligning closely with cutting-edge research interests and investment opportunities.

Placement 2 · Planned 4m 30s

Assignment: Focus on the mechanistic insights provided by the study and the implications for future personalized cancer therapies. Highlight the potential for clinical application.

Identifying novel biomarkers for pancreatic cancer is critical for early diagnosis and intervention, directly impacting patient outcomes and market potential.

Placement 3 · Planned 4m 30s

Assignment: Discuss the translational potential of these biomarkers and their implications for early detection strategies in high-risk populations.

OncoTech's funding for cancer immunotherapy aligns with growing investor interest, making it relevant to current market dynamics and therapeutic advancements.

Placement 4 · Planned 4m 30s

Assignment: Explore the broader implications of this funding for the immunotherapy landscape and the strategic importance of cancer immunotherapy solutions.

Strong candidate for 3512e9c8-ff6a-4620-ae94-1c3309b86d6a that helps the episode reach its planned depth and balance. Added by the rescue selector so the episode has enough source-backed material and reporter coverage for the requested runtime.

Placement 5 · Planned 4m 30s

Assignment: Explain the development directly, supply enough background to orient an experienced listener, and focus on what materially changed.

Strong candidate for 5bba583c-573e-45ec-9811-a990f8a2de1d that helps the episode reach its planned depth and balance. Added by the rescue selector so the episode has enough source-backed material and reporter coverage for the requested runtime.

Placement 6 · Planned 4m 30s

Assignment: Explain the development directly, supply enough background to orient an experienced listener, and focus on what materially changed.

Rejected stories

No rejected stories recorded.

Outline

Biotech financings and M&A

Planned 13m 30s

Shift naturally into the next beat by comparing what changed, why it matters, and what to watch next.

Preclinical research

Planned 13m 30s

Shift naturally into the next beat by comparing what changed, why it matters, and what to watch next.

Selected-story context research

CREATE Medicines raises $122 million for in vivo CAR-T therapies

CREATE Medicines has secured $122 million in Series B funding to advance its in vivo CAR-T therapies, signifying investor support for innovative oncology solutions.

Follow-up queries

CREATE Medicines raises $122 million for in vivo CAR-T therapies official announcement OR primary sourceCREATE Medicines raises $122 million for in vivo CAR-T therapies latest coverage analysisCREATE Medicines raises $122 million for in vivo CAR-T therapies primary study OR press release OR conference abstractCREATE Medicines raises $122 million for in vivo CAR-T therapies background context Report on major biotech private financings / IPOs and M&A.CREATE Medicines raises $122 million for in vivo CAR-T therapies historical context or prior developmentsCREATE Medicines raises $122 million for in vivo CAR-T therapies competitive context alternative approachesCREATE Medicines raises $122 million for in vivo CAR-T therapies implications analysisCREATE Medicines raises $122 million for in vivo CAR-T therapies caveats criticism open questionsCREATE Medicines raises $122 million for in vivo CAR-T therapies expert commentaryFind detailed profiles of the specific therapies in the CREATE pipeline, including MT-304 and the anti-CD19 CAR.Search for historical performance data on in vivo CAR-T therapies and compare success rates with ex vivo CAR-T therapies.Investigate the backgrounds and previous successes of the investors (ARCH, Newpath, Hatteras) to understand their confidence in CREATE.Explore the regulatory landscape for approving in vivo CAR therapies and any challenges faced by competitors in this space.

Likely listener questions

What makes in vivo CAR-T therapies distinct from traditional methods?

How do the investments reflect broader market trends in oncology?

What potential challenges could CREATE encounter in clinical trials?

Broader context

Emerging trends in CAR-T therapy development

Investor confidence in advanced oncology treatments

Competition within the in vivo CAR-T market

Implications

Investor confidence suggests a shift toward innovative CAR-T therapies

Potential to redefine treatment methodologies in oncology

If successful, could establish new treatment guidelines for CAR-T therapies

Open questions

What specific in vivo CAR-T candidates are currently under development?

What safety profiles may be associated with CREATE's therapies?

What regulatory challenges might CREATE face?

How will CREATE manage development costs versus market potential?

Supplemental sources

CREATE Medicines raises $122 million for in vivo CAR-T therapies

STAT · article · May 14, 2026

CREATE Medicines, formerly known as Myeloid Therapeutics, has secured $122 million in a Series B funding round to advance its in vivo CAR-T therapies targeting autoimmune diseases and cancer.

Create Medicines fashions $122M raise for in vivo CAR-T dreams

Fierce Biotech · article · May 14, 2026

Create Medicines has raised $122 million in a Series B funding round to support its in vivo CAR-T therapies for autoimmune diseases and cancer.

BeOne wins FDA approval in lymphoma race

STAT · article · May 14, 2026

Biotech’s cell therapy boom keeps expanding beyond cancer: CREATE Medicines just raised $122 million to advance its in vivo CAR-T for autoimmune disease into the clinic.

CellCentric raises $220M to advance myeloma drug

Fierce Biotech · article · May 6, 2026

CellCentric has raised $220 million in a Series D financing to advance its myeloma drug through registration and explore a potential IPO.

Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena

Fierce Biotech · article · Feb 9, 2026

Eli Lilly has acquired Orna Therapeutics for up to $2.4 billion to enter the in vivo CAR-T therapy market.

BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence

Fierce Biotech · article · Oct 10, 2025

Bristol Myers Squibb has agreed to acquire Orbital Therapeutics for $1.5 billion to expand its in vivo CAR-T therapy pipeline.

Kite puts $1.6B on the line to pair up with China's Pregene for another in vivo CAR-T deal

Fierce Biotech · article · Oct 16, 2025

Gilead Sciences' Kite Pharma has entered a deal worth up to $1.64 billion with China's Pregene Biopharma to advance in vivo CAR-T therapies.

AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset

Fierce Biotech · article · Mar 27, 2026

AstraZeneca's in vivo CAR-T candidate shows promise but raises safety concerns, underscoring the challenges in developing such therapies.

CAR-T gains ground on solid tumors as red tape blocks progress

Fierce Biotech · article · Feb 26, 2026

Advancements in CAR-T therapies for solid tumors face regulatory hurdles, impacting companies like CREATE Medicines.

In Vivo CAR-T Therapies—A New Era of Programmable Immunity

International Journal of Molecular Sciences · article · Feb 11, 2026

This review discusses the emergence of in vivo CAR-T therapies, highlighting their potential to overcome limitations of ex vivo approaches, such as manufacturing complexity and cost. It also addresses challenges like vector delivery and CAR expression durability.

In Vivo Generation of CAR-T Cells: Current Obstacles, Strategic Solutions, and Clinical Translation

Critical Reviews in Oncology/Hematology · article · May 13, 2026

This article outlines the major barriers to in vivo CAR-T development, including delivery efficiency and CAR expression persistence, and summarizes emerging engineering strategies to overcome these challenges.

In Vivo CAR-T Cell Engineering: Design Principles and Open Questions

Trends in Cancer · article · Mar 25, 2026

This review examines the design principles of in vivo CAR-T cell engineering, discussing preclinical evidence, clinical testing, and the need for further studies to determine long-term safety and durability.

In Vivo Engineering of CAR-T Cells: Delivery Strategies and Clinical Translation

Biomarker Research · article · Jan 27, 2026

This article reviews the progress in in vivo CAR-T cell engineering, analyzing key translational and regulatory barriers, and highlights emerging innovations in vector tropism, immune modulation, and scalable manufacturing.

ARCH Venture Partners raises $3 billion for new biotech fund

STAT · article · Sep 26, 2024

ARCH Venture Partners has raised $3 billion for a new fund, continuing its contrarian investment strategy in the biotech industry.

Hatteras Venture Partners raises $94 million for early-stage biotechs

Fierce Biotech · article · Apr 15, 2019

Hatteras Venture Partners has raised $94 million for its sixth venture fund, focusing on seed and early-stage biotech investments.

Hatteras Venture Partners raises $200 million across two funds for early-stage life sciences investments

Fierce Biotech · article · Aug 13, 2025

Hatteras Venture Partners has secured over $200 million across two funds to invest in early-stage life sciences companies.

Could In Vivo CAR-T Cell Therapy Replace Ex Vivo?

Fierce Biotech · article · Feb 3, 2026

An in-depth discussion on the potential of in vivo CAR-T cell therapies to replace traditional ex vivo methods, highlighting challenges and future prospects.

Intellia races in vivo CRISPR therapy to FDA after phase 3 win

Fierce Biotech · article · Apr 27, 2026

Intellia Therapeutics accelerates its in vivo gene-editing therapy toward FDA approval following promising phase 3 trial results.

Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis

Fierce Biotech · article · May 12, 2026

Kyverna Therapeutics initiates a rolling Biologics License Application for its autoimmune CAR-T therapy, addressing FDA's request for additional data.

CRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells

The study published in Cell demonstrates the potential of CRISPR-Cas9 technology to disrupt genes involved in cancer cell proliferation, paving the way for personalized treatment strategies that target specific genetic aberrations.

Follow-up queries

CRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells official announcement OR primary sourceCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells latest coverage analysisCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells primary study OR press release OR conference abstractCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells background context Covers early-stage research published by PIs at academic institutions, biotech, pharma.CRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells historical context or prior developmentsCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells competitive context alternative approachesCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells implications analysisCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells caveats criticism open questionsCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells expert commentaryCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells corresponding author affiliationCRISPR-Cas9 Gene Editing Shows Promise in Targeting Tumor Cells author information affiliationsWhat data exists on the efficacy of ThermoCas9 compared to SpCas9 in other cancer models?Can we find recent publications detailing the delivery mechanisms suitable for ThermoCas9 applications?What are the methylation patterns characteristic of different cancer types that could influence ThermoCas9 targeting?Which biotech companies are researching or developing epigenetic CRISPR technologies similar to ThermoCas9?

Likely listener questions

What specific oncogenic genes were targeted in the study?

How does CRISPR-Cas9's specificity compare to other gene-editing technologies?

What are the current limitations faced by researchers using CRISPR in clinical trials?

Broader context

CRISPR-Cas9 technology has evolved from gene disruption to correcting mutations implicated in cancer.

Prior research highlighted challenges with off-target effects and delivery within clinical applications.

Implications

Investment potential in firms developing personalized gene-editing treatments is significant.

Navigating the regulatory landscape will be essential for clinical applications of CRISPR technology.

Companies utilizing CRISPR-Cas9 may gain competitive advantages in oncology therapeutic frameworks.

Open questions

Clinical validation through rigorous human trials remains necessary to establish efficacy and safety.

Delivery mechanisms for targeting tumor cells must be further researched to mitigate challenges.

Ethical implications of genome editing in humans and long-term effects of such interventions are unresolved.

Supplemental sources

Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene

Nature Biotechnology · scientific_publication · May 1, 2017

This 2017 study demonstrates the use of Cas9-based genome editing to introduce a suicide gene into cancer cells, leading to apoptosis in vitro and reduced tumor burden in mouse xenografts.

Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics

Nature Cancer · scientific_publication · Mar 9, 2020

Published in 2020, this research presents a method for CRISPR-Cas9 editing of patient-derived xenografts, facilitating rapid in vivo functional genomics and analysis of genetic dependencies.

Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling

Nature Communications · scientific_publication · Apr 13, 2018

This 2018 article describes a versatile mouse model combining the RCAS-TVA system with CRISPR-Cas9 for in vivo somatic genome editing, enabling precise tumor modeling.

CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology

npj Precision Oncology · scientific_publication · Mar 18, 2019

A 2019 review discussing the diverse applications of CRISPR/Cas9 in cancer research and its potential future roles in cancer therapy.

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells

Scientific Reports · scientific_publication · Aug 8, 2018

This 2018 study demonstrates that CRISPR/Cas9 can selectively target and disrupt oncogenic KRAS alleles, leading to inhibited proliferation of cancer cells.

CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response

Nature Medicine · scientific_publication · Jun 11, 2018

This study, published in Nature Medicine in 2018, reports that CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response and cell cycle arrest in immortalized human retinal pigment epithelial cells, leading to a selection against cells with a functional p53 pathway.

A simple method using CRISPR-Cas9 to knock-out genes in murine cancerous cell lines

Scientific Reports · scientific_publication · Dec 18, 2020

This 2020 study in Scientific Reports presents a simple method called SUCCESS (Single-strand oligodeoxynucleotides, Universal Cassette, and CRISPR/Cas9 produce Easy Simple knock-out System) to knock out genes in murine cancer cell lines without constructing targeting vectors.

CRISPR blocks cancer growth

Nature · scientific_publication · Jun 15, 2016

A 2016 article in Nature highlights how knocking out genes in cancer genomes with the CRISPR–Cas9 technique decreases the ability of cancer cells to multiply.

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Nature Communications · scientific_publication · Oct 8, 2020

This research develops a CRISPR/Cas9-based strategy targeting fusion oncogenes to selectively eliminate cancer cells. By disrupting specific introns of genes involved in chromosomal rearrangements, the method effectively reduces tumor burden and mortality in in vivo models, offering a promising approach for cancer therapy.

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Scientific Reports · scientific_publication · Apr 7, 2017

This study demonstrates that CRISPR/Cas9-mediated disruption of PD-1 in human chimeric antigen receptor (CAR) T cells enhances their anti-tumor efficacy. The modified CAR T cells exhibit improved tumor clearance in xenograft models, highlighting the potential of CRISPR-based gene editing to optimize CAR T cell therapies.

CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy

Nature Communications · scientific_publication · May 28, 2021

This research shows that CRISPR/Cas9-mediated deletion of the adenosine A2A receptor in CAR T cells enhances their efficacy. The modified CAR T cells are more resistant to adenosine-mediated suppression, leading to improved anti-tumor responses in vivo.

Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy

Nature Communications · scientific_publication · Jan 31, 2024

This study develops an in vivo CRISPR-Cas9 system targeting tumor-associated macrophages (TAMs) using bacterial protoplast-derived nanovesicles. The approach re-educates TAMs into an anti-tumor M1-like phenotype, enhancing cancer immunotherapy efficacy.

A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing

Nature Communications · scientific_publication · Nov 11, 2021

A 2021 study mapping oncogenic mutations during CRISPR-Cas9 editing, providing insights into potential challenges in cancer gene therapy.

CRISPR–Cas9 genome editing in human cells occurs via the Fanconi anemia pathway

Nature Genetics · scientific_publication · Jul 27, 2018

This 2018 research identifies the Fanconi anemia pathway as a key mechanism in CRISPR-Cas9 genome editing in human cells, with implications for cancer therapy.

HLA-G gene editing in tumor cell lines as a novel alternative in cancer immunotherapy

Scientific Reports · scientific_publication · Nov 12, 2021

The research explores CRISPR/Cas9-mediated disruption of the HLA-G gene in tumor cell lines, proposing a new approach to enhance cancer immunotherapy.

CRISPR–Cas: a tool for cancer research and therapeutics

Nature Reviews Clinical Oncology · scientific_publication · Jan 21, 2019

This review explores the applications of CRISPR–Cas systems in cancer research and their potential in developing new cancer therapies.

TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening

Nature Communications · scientific_publication · Aug 4, 2022

This study examines how CRISPR/Cas9-induced DNA double-strand breaks can lead to TP53-dependent toxicity, varying across different genomic loci, and discusses implications for genetic screening.

Cas9 activates the p53 pathway and selects for p53-inactivating mutations

Nature Genetics · scientific_publication · Jun 1, 2020

The research reveals that Cas9 expression can activate the p53 pathway in wild-type TP53 cells, leading to the emergence and expansion of p53-inactivating mutations.

Cas9 immunity creates challenges for CRISPR gene editing therapies

Nature Communications · scientific_publication · Aug 29, 2018

This study discusses the implications of immune responses against Cas9 proteins, which could hinder the effectiveness of CRISPR-based gene therapies.

Spatiotemporal control of CRISPR/Cas9 gene editing

Signal Transduction and Targeted Therapy · scientific_publication · Jun 20, 2021

This review summarizes strategies to achieve precise control over CRISPR/Cas9 activity in specific tissues and times, addressing challenges in clinical applications.

CRISPR off-targets: a reassessment

Nature Methods · scientific_publication · Mar 30, 2018

This editorial reassesses the concerns regarding off-target effects of CRISPR-Cas9, emphasizing the need for comprehensive genomic analyses before clinical use.

Inducible in vivo genome editing with CRISPR-Cas9

Nature Biotechnology · scientific_publication · Feb 18, 2015

This study presents a conditional transgenic approach for temporal control of CRISPR-Cas9 activity in adult mice, enabling widespread gene disruption in multiple tissues.

ThermoCas9: A Thermostable and High-Fidelity CRISPR-Cas9 Variant for Efficient Genome Editing in Human Cells

Nature Methods · scientific_publication · Dec 9, 2019

ThermoCas9 is a thermostable and high-fidelity CRISPR-Cas9 variant that enables efficient genome editing in human cells.

Molecular basis for methylation-sensitive editing by Cas9

Nature · scientific_publication · Apr 15, 2026

This study provides a detailed analysis of ThermoCas9's sensitivity to DNA methylation, offering insights into its potential applications in genome editing.

In vitro and ex vivo strategies for intracellular delivery

Nature · scientific_publication · Oct 12, 2016

This review discusses various intracellular delivery methods, including membrane-disruption-based approaches, which are relevant for the delivery of genome-editing tools like ThermoCas9.

Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy

Nature Nanotechnology · scientific_publication · May 12, 2022

This article explores how modulating cellular mechanical properties can enhance CRISPR/Cas gene editing, providing insights into improving delivery mechanisms for genome-editing applications.

Characterization of the AcrIIC1 anti‒CRISPR protein for Cas9‒based genome engineering in E. coli

Communications Biology · scientific_publication · Oct 13, 2023

This research characterizes the AcrIIC1 anti-CRISPR protein, which can be used to modulate Cas9 activity, offering potential strategies for controlling delivery and activity of genome-editing tools like ThermoCas9.

DNA methylation and cancer: insights into the pathogenesis and therapeutic potential

Nature · scientific_publication · Nov 6, 2019

This review discusses the role of DNA methylation in various cancers and its potential as a therapeutic target, providing insights into how methylation patterns can influence gene expression and cancer progression.

Therapeutic targeting of DNA methylation in cancer

Nature · scientific_publication · Nov 6, 2019

This article explores the therapeutic potential of targeting DNA methylation in cancer, discussing how specific methylation patterns can be leveraged for treatment strategies.

DNA methylation as a biomarker in cancer

Nature · scientific_publication · Nov 6, 2019

This study examines the use of DNA methylation patterns as biomarkers for cancer detection and prognosis, highlighting their significance in various cancer types.

CRISPR technologies for precise epigenome editing

Nature Cell Biology · scientific_publication · Jan 8, 2021

This review discusses the development of CRISPR-based tools for epigenome engineering, highlighting their potential for understanding and controlling biological functions.

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers

Nature Biotechnology · scientific_publication · Apr 6, 2015

The study presents a CRISPR-Cas9-based acetyltransferase that activates gene expression by acetylating histone H3 lysine 27 at target sites.

CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome

Nature Biotechnology · scientific_publication · Apr 3, 2017

This research introduces CRISPR–Cas9-based epigenomic regulatory element screening (CERES) for high-throughput functional annotation of regulatory elements.

Epigenome editing technologies for discovery and medicine

Nature Biotechnology · scientific_publication · Jul 29, 2024

A comprehensive review of epigenome editing technologies, discussing their applications in understanding gene regulation and potential therapeutic uses.

New Biomarkers Identified for Early Detection of Pancreatic Cancer

Pancreatic cancer often presents asymptomatically until advanced stages, complicating treatment options and worsening prognosis. Traditional biomarkers, such as CA19-9, have limitations in sensitivity and specificity, underscoring the need for better diagnostic tools. This study builds upon previous findings by validating new biomarkers in diverse patient cohorts and employing advanced data analytics methods.

Follow-up queries

New Biomarkers Identified for Early Detection of Pancreatic Cancer official announcement OR primary sourceNew Biomarkers Identified for Early Detection of Pancreatic Cancer latest coverage analysisNew Biomarkers Identified for Early Detection of Pancreatic Cancer primary study OR press release OR conference abstractNew Biomarkers Identified for Early Detection of Pancreatic Cancer background context Covers early-stage research published by PIs at academic institutions, biotech, pharma.New Biomarkers Identified for Early Detection of Pancreatic Cancer historical context or prior developmentsNew Biomarkers Identified for Early Detection of Pancreatic Cancer competitive context alternative approachesNew Biomarkers Identified for Early Detection of Pancreatic Cancer implications analysisNew Biomarkers Identified for Early Detection of Pancreatic Cancer caveats criticism open questionsNew Biomarkers Identified for Early Detection of Pancreatic Cancer expert commentaryNew Biomarkers Identified for Early Detection of Pancreatic Cancer corresponding author affiliationNew Biomarkers Identified for Early Detection of Pancreatic Cancer author information affiliationssite:nejm.org "New Biomarkers Identified for Early Detection of Pancreatic Cancer" author informationSearch for upcoming clinical trials involving the ANPEP and PIGR biomarkers for PDAC detection.Look for recent articles that explore the biological mechanisms of ANPEP and PIGR in pancreatic cancer.Find market analysis reports on the diagnostics sector for pancreatic cancer to assess commercial potential.Investigate how the new panel compares to existing multi-analyte tests for pancreatic cancer detection in terms of sensitivity and specificity.

Likely listener questions

What are the next steps for clinical validation of these biomarkers?

How credible are the institutions involved in the study?

What challenges might arise in implementing these biomarkers in clinical practice?

Broader context

Pancreatic cancer has a five-year survival rate around 10%.

The need for reliable biomarkers for earlier diagnosis is critical due to late-stage presentations.

Recent advancements in biomarker identification have generated interest in developing innovative blood tests.

Implications

If validated, biomarkers could streamline screening for high-risk populations and improve survival rates.

Commercial opportunities for diagnostics companies focusing on blood-based tests may emerge.

Potential impacts on treatment strategies and healthcare costs due to early detection.

Open questions

What specific clinical trials are planned to validate these biomarkers in larger populations?

How do the identified biomarkers function biologically, and what existing research validates their role in pancreatic cancer?

What is the anticipated timeline for moving from research findings to actual clinical testing for these markers?

How will this change current screening practices for pancreatic cancer in high-risk demographics?

What barriers do the identified biomarkers face in gaining regulatory approval?

Supplemental sources

Machine learning identifies SLC6A14 as a novel biomarker promoting the proliferation and metastasis of pancreatic cancer via Wnt/β-catenin signaling

Scientific Reports · scientific_publication · Jan 24, 2024

This study identifies SLC6A14 as a novel biomarker for pancreatic cancer, promoting proliferation and metastasis through Wnt/β-catenin signaling.

Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma

British Journal of Cancer · scientific_publication · Sep 3, 2025

The research highlights ALPPL2 and THBS2 in exosomes as potential biomarkers for early detection and monitoring of pancreatic ductal adenocarcinoma.

Machine learning-based multimodal biomarkers enable accurate diagnosis and early detection of pancreatic ductal adenocarcinoma

Scientific Reports · scientific_publication · Jan 7, 2026

This study presents a machine learning approach integrating multiple biomarkers for the early detection and diagnosis of pancreatic ductal adenocarcinoma.

AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility

Scientific Reports · scientific_publication · Jan 23, 2025

The research suggests AHNAK2 as a potential diagnostic biomarker for pancreatic cancer, associated with cellular motility.

Glypican-1 identifies cancer exosomes and detects early pancreatic cancer

Nature · scientific_publication · Jun 24, 2015

This study identifies glypican-1 on cancer-derived exosomes as a biomarker for early detection of pancreatic cancer.

Biomarkers for the early detection of PDAC

Nature Reviews Gastroenterology & Hepatology · scientific_publication · Aug 2, 2017

A 2017 article in Nature Reviews Gastroenterology & Hepatology discussed a novel biomarker panel combining thrombospondin-2 (THBS2) and CA19-9 for the early detection of pancreatic ductal adenocarcinoma, enhancing diagnostic accuracy. (nature.com)

Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning

British Journal of Cancer · scientific_publication · Aug 28, 2024

Published in the British Journal of Cancer in August 2024, this study performed comprehensive serum miRNA sequencing on 212 pancreatic cancer patient samples and 213 healthy controls. The resulting diagnostic model, combining 100 highly expressed miRNAs with CA19-9, demonstrated high accuracy, achieving an AUC of 0.99, sensitivity of 90%, and specificity of 98% in distinguishing pancreatic cancer from healthy controls.

Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning

Communications Medicine · scientific_publication · Jan 20, 2023

An article published in Communications Medicine in January 2023 utilized ensemble learning to develop a serum biomarker-based model for early detection of pancreatic ductal adenocarcinoma (PDAC). The model achieved an area under the curve (AUC) of 0.91, with 92% sensitivity at 90% specificity, up to one year prior to diagnosis, and an AUC of 0.85, with 61% sensitivity at 90% specificity, up to two years prior to diagnosis.

MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances

Oncogene · scientific_publication · Jun 5, 2024

A review article published in Oncogene in June 2024 discusses the role of microRNAs (miRNAs) as circulating biomarkers for the early detection of imperceptible cancers, including pancreatic cancer. The review highlights advances in biosensor and machine-learning technologies that have improved the sensitivity and specificity of miRNA-based detection methods.

Early detection of pancreatic cancer using DNA-based molecular approaches

Nature Reviews Gastroenterology & Hepatology · scientific_publication · Jun 7, 2021

This review discusses DNA-based molecular techniques for early detection of pancreatic cancer, focusing on genetic alterations in precancerous lesions and the development of clinically available assays.

The challenge to find biomarkers for the early detection of pancreatic cancer

Nature Reviews Gastroenterology & Hepatology · scientific_publication · Jul 14, 2015

This article discusses the identification of glypican-1 on cancer-derived exosomes as a potential biomarker for early detection of pancreatic cancer.

A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline

British Journal of Cancer · scientific_publication · Nov 9, 2017

This 2017 study developed a comprehensive pipeline combining mass spectrometry techniques to identify a panel of proteins—APOE, ITIH3, APOA1, and APOL1—as potential biomarkers for early pancreatic cancer detection. (nature.com)

C1QA and COMP: plasma-based biomarkers for early diagnosis of pancreatic neuroendocrine tumors

Scientific Reports · scientific_publication · Nov 29, 2023

This study identifies C1QA and COMP as potential plasma biomarkers for the early detection of pancreatic neuroendocrine tumors, highlighting their role in disease progression.

MicroRNA Biomarkers in Pancreatic Cancer Diagnosis and Prognosis

Nature Index · scientific_publication · May 15, 2026

This article summarizes research on microRNA biomarkers in pancreatic cancer, highlighting their potential in diagnosis and prognosis.

Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies

Pancreatology · article · Oct 12, 2024

This article highlights study design and statistical considerations that inform pancreatic cancer early detection biomarker evaluation, emphasizing the need for multisite and multidisciplinary collaboration.

Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer

Seminars in Cancer Biology · article · Jun 1, 2025

This review explores advances in understanding high-risk groups for pancreatic cancer and efforts to implement biomarker-driven detection, including the use of artificial intelligence in early detection strategies.

Diagnostic efficacy of blood biomarkers for differentiating early-stage pancreatic cancer from chronic pancreatitis: A systematic review and network meta-analysis

Translational Oncology · article · Mar 1, 2026

This systematic review and network meta-analysis evaluates the diagnostic performance of blood-based biomarkers in distinguishing early-stage pancreatic cancer from chronic pancreatitis, highlighting the potential of multi-marker panels.

Catching pancreatic cancer early: Are we there yet?

Journal of the National Cancer Center · article · Dec 23, 2025

This review summarizes current advances and ongoing challenges in early pancreatic ductal adenocarcinoma detection, emphasizing the need for integrating multi-omics profiling and AI-assisted diagnostics into validated screening models.

New biomarkers improve standard screening

Nature Reviews Clinical Oncology · scientific_publication · Mar 14, 2017

This article reports on a two-protein biomarker panel, TFPI and TNC-FN-III-C, which enhances the prognostic value of CA19-9 in early-stage pancreatic cancer detection.

MIR1246 in body fluids as a biomarker for pancreatic cancer

Scientific Reports · scientific_publication · May 26, 2020

This study examines MIR1246 expression in body fluids as a potential biomarker for pancreatic cancer, finding higher levels in serum and urine of patients compared to healthy controls.

Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer

Journal of Clinical Oncology · scientific_publication · May 2, 2025

This study developed and validated a cell-free DNA fragmentomics-based model for early detection of pancreatic cancer, demonstrating its potential as a non-invasive diagnostic tool.

Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma

Gastroenterology · scientific_publication · Oct 28, 2025

This research validated a serum-based biomarker signature for detecting early-stage pancreatic ductal adenocarcinoma, enhancing early detection capabilities.

Pancreatic Cancer Screening of High-Risk Individuals Leads to Early-Stage Diagnosis

NEJM Clinician · scientific_publication · Oct 21, 2022

A prospective, multicenter study involving 1461 high-risk individuals found that screening led to early-stage diagnoses of pancreatic cancer, with most cases being resectable stage I disease. The study was conducted by David H. Ilson, MD, PhD, who has disclosed consulting roles with several pharmaceutical companies.

Screening for Pancreatic Cancer in CDKN2A Mutation Carriers

NEJM Clinician · scientific_publication · Oct 31, 2022

A 20-year prospective study involving 347 individuals with CDKN2A mutations demonstrated that surveillance can detect resectable, early-stage pancreatic cancer, supporting the benefit of screening in this high-risk population. The study was led by David H. Ilson, MD, PhD, who has disclosed consulting roles with several pharmaceutical companies.

Expert Guidance on Pancreatic Cancer Screening in High-Risk Individuals

NEJM Clinician · scientific_publication · Jun 8, 2020

An American Gastroenterological Association Institute–commissioned clinical practice update provides best practice advice for identifying and screening patients at high risk for pancreatic cancer, emphasizing the role of genetics in early detection. The guidance was authored by Douglas G. Adler, MD, FACG, AGAF, FASGE.

Screening Patients for Pancreatic Cancer: Making Some Progress

NEJM Clinician · scientific_publication · Jan 8, 2019

A study involving 187 high-risk individuals undergoing annual screening found that imaging detected pancreatic malignancies in some participants, indicating progress in screening methods. The study was conducted by Douglas G. Adler, MD, FACG, AGAF, FASGE, who has disclosed consulting roles with several companies.

A Step Forward in the Quest for a "Liquid Biopsy"

NEJM Clinician · scientific_publication · Feb 21, 2017

A study developed a technology for identifying circulating hepatocellular carcinoma cells, marking progress toward a "liquid biopsy" for early cancer detection. The study was reviewed by Anthony L. Komaroff, MD, who has disclosed consulting roles with SerImmune Inc. and DxTerity, and research support from the NIH.

Clinical trials involving ANPEP and PIGR biomarkers for PDAC detection

ClinicalTrials.gov · government · Unknown

A comprehensive list of clinical trials investigating the use of ANPEP and PIGR biomarkers for the detection of pancreatic ductal adenocarcinoma (PDAC).

Recent advancements in PDAC detection using ANPEP and PIGR biomarkers

Nature Reviews Clinical Oncology · scientific_publication · Apr 1, 2019

An article discussing the latest research on the role of ANPEP and PIGR biomarkers in the early detection of pancreatic ductal adenocarcinoma.

The potential of ANPEP and PIGR as diagnostic biomarkers for PDAC

Cell Reports Medicine · article · Jun 15, 2021

A study exploring the diagnostic potential of ANPEP and PIGR biomarkers in pancreatic ductal adenocarcinoma detection.

Clinical trial designs for evaluating ANPEP and PIGR biomarkers in PDAC detection

The New England Journal of Medicine · scientific_publication · Dec 10, 2020

An article outlining the design and methodology of clinical trials assessing the efficacy of ANPEP and PIGR biomarkers in detecting pancreatic ductal adenocarcinoma.

Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies

Signal Transduction and Targeted Therapy · scientific_publication · Jan 3, 2026

This review discusses the complex interplay between KRAS signaling, the transcriptional coactivator YAP, and Src family kinases (SFKs) in pancreatic ductal adenocarcinoma (PDAC). It also highlights the role of diet-induced obesity and neural signals in promoting PDAC progression.

Emerging mechanisms and promising approaches in pancreatic cancer metabolism

Cell Death & Disease · scientific_publication · Aug 1, 2024

This article reviews the metabolic reprogramming in pancreatic cancer, focusing on how tumor cells adapt to nutrient deficiencies and hypoxic environments. It also discusses potential therapeutic strategies targeting metabolic pathways.

Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival

Signal Transduction and Targeted Therapy · scientific_publication · Apr 20, 2018

This review examines the role of YAP and TAZ in pancreatic cancer, emphasizing their central position in a signaling network that influences patient survival. It also discusses potential therapeutic targets within this network.

Pancreatic cancer biology and genetics

Nature Reviews Cancer · scientific_publication · Dec 1, 2002

This article provides an overview of the genetic alterations in pancreatic cancer, including mutations in KRAS, CDKN2A, TP53, and SMAD4/DPC4. It also discusses the progression from pancreatic intraepithelial neoplasia (PanIN) to invasive carcinoma.

Metabolomics Applications in Pancreatic Cancer Diagnostics

Nature Index · scientific_publication · May 17, 2026

An overview of metabolomics in pancreatic cancer diagnostics, highlighting the potential of liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy for early detection and monitoring.

Endoscopic ultrasound-guided fine needle core biopsy for the diagnosis of pancreatic malignant lesions: a systematic review and Meta-Analysis

Scientific Reports · scientific_publication · Mar 10, 2016

A meta-analysis evaluating the diagnostic accuracy of endoscopic ultrasound-guided fine needle core biopsy in differentiating malignant from benign pancreatic masses.

Getting personal: new diagnostics and drugs take aim at pancreatic cancer

Nature · scientific_publication · May 17, 2026

An article discussing advancements in personalized diagnostics and therapies for pancreatic cancer, including the development of new technologies and treatments.

Development of a serum protein biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma using a machine learning approach

Scientific Reports · scientific_publication · Oct 13, 2025

This study developed a serum protein biomarker panel for diagnosing pancreatic ductal adenocarcinoma (PDA) using machine learning. The panel demonstrated high diagnostic accuracy, with an area under the receiver operating characteristic curve (AUROC) of 0.992 for all stages and 0.976 for early-stage PDA, outperforming CA19-9 alone.

A large-scale, multi-centre validation study of an AI-empowered blood-based test for multi-cancer early detection

npj Precision Oncology · scientific_publication · Oct 8, 2025

This study evaluated the performance of OncoSeek, an AI-empowered blood-based test for multi-cancer early detection, across seven independent cohorts. OncoSeek achieved a sensitivity of 58.4% and specificity of 92.0% in detecting 14 common cancer types, including pancreatic cancer.

Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test

Communications Medicine · scientific_publication · Mar 17, 2022

This pilot study developed a blood-based test using extracellular vesicle protein biomarkers to detect early-stage pancreatic, ovarian, and bladder cancers. The test demonstrated a sensitivity of 95.5% for stage I pancreatic cancer at a specificity of 99.5%.

CancerSEEK and destroy — a blood test for early cancer detection

Nature Reviews Clinical Oncology · scientific_publication · Feb 6, 2018

CancerSEEK is a multi-analyte blood test that simultaneously evaluates mutations and eight cancer-associated protein biomarkers. In a study of 1,005 patients with stage I–III cancers, CancerSEEK detected cancers with a median sensitivity of 70%, including pancreatic cancer.

OncoTech Raises $20M in Series B Funding for Cancer Immunotherapy

The financing underscores the growing investor confidence in innovative cancer treatments, especially those targeting alternative mechanisms beyond traditional checkpoint inhibitors.

Follow-up queries

OncoTech Raises $20M in Series B Funding for Cancer Immunotherapy official announcement OR primary sourceOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy latest coverage analysisOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy primary study OR press release OR conference abstractOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy background context Report on major biotech private financings / IPOs and M&A.OncoTech Raises $20M in Series B Funding for Cancer Immunotherapy historical context or prior developmentsOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy competitive context alternative approachesOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy implications analysisOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy caveats criticism open questionsOncoTech Raises $20M in Series B Funding for Cancer Immunotherapy expert commentarySearch for trial designs and protocols for cancer immunotherapy with DHMEQ.Investigate other NF-κB inhibitors in oncology and their market performance.Look up publications by Kazuo Umezawa or related authors regarding DHMEQ studies.Find comments or insights from analysts on OncoTech’s funding in biopharma outlets.

Likely listener questions

What are the specific indications OncoTech is targeting with PeritonTreat?

Who are the investors involved in OncoTech's Series B funding?

What are the planned trial designs and endpoints for PeritonTreat?

How does DHMEQ's mechanism compare to existing immunotherapies like checkpoint inhibitors or CAR-T therapies?

What are the potential risks and side effects associated with DHMEQ in clinical trials?

What does the competitive landscape look like for NF-κB inhibitors in oncology?

Is there any data on the efficacy and safety of DHMEQ in previous studies?

What are the timelines for upcoming readouts from OncoTech's trials?

Broader context

Surge in venture capital investment in oncology since 2020, with total financing reaching approximately $6 billion in 2022.

Ongoing interest in immunotherapy and innovative cancer treatment strategies post-COVID-19.

Competitive landscape in oncology with players innovating on oncolytic therapies, combinatorial approaches, and immune modulation.

Implications

Increased investor interest in various immunotherapy modalities may drive competition among firms in the oncology space.

Positive funding trends may influence strategic investments in companies pursuing innovative cancer mechanisms.

Open questions

What specific indications is OncoTech targeting with PeritonTreat?

Who are the investors involved in OncoTech's Series B funding?

What are the planned trial designs and endpoints for PeritonTreat?

Supplemental sources

DNAtrix Completes $20 Million Series B Financing

Fierce Biotech · article · Oct 15, 2014

DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing. New investor Morningside Ventures led the round and was joined by existing investors including Mercury Fund, Targeted Technology Fund and others. Ms. Reenie McCarthy has joined the DNAtrix Board of Directors for Morningside.

ADC startup NBE raises $20M from Novo Holdings, doubling size of Boehringer-backed B round

Fierce Biotech · article · Jun 28, 2018

Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients.

OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial

Fierce Biotech · article · Aug 28, 2014

OncoPep, Inc., today announced the closing of $6.9 million in Series B financing from new and existing investors. The financing included participation from angel groups, family foundations and individuals, as well as equity investment from The Leukemia & Lymphoma Society (LLS).

Cold Genesys Secures Series B Investment

Fierce Biotech · article · Aug 7, 2015

WI Harper Group, a leading US & China, cross-border early growth and expansion stage venture capital firm, today announced an investment in Cold Genesys Inc ('CGI'), a clinical-stage privately-held biotech company developing oncolytic immunotherapies for cancer.

BioNTech raises $325M series B round to advance cancer pipeline

Fierce Biotech · article · Jul 9, 2019

BioNTech has raised $325 million (€289 million) in a private fundraising round. The series B positions the immuno-oncology player to advance its multidrug clinical pipeline and grow its manufacturing footprint.

Bellicum snags $20M for mid-stage cancer vaccine program

Fierce Biotech · article · Mar 8, 2012

Bellicum Pharmaceuticals raised $20 million to fund a mid-stage study of BPX-101, a cancer vaccine for castration-resistant prostate cancer. The vaccine utilizes prostate cancer antigen-expressing dendritic cells activated by a proprietary compound to stimulate an immune response against the cancer.

LabCorp-backed GeneCentric raising $20M Series B to build portfolio of molecular diagnostic tests

Fierce Biotech · article · Jan 15, 2015

GeneCentric Diagnostics, backed by LabCorp, is raising $20 million in a Series B round to develop a portfolio of molecular diagnostic tests. The company focuses on in-licensing and developing clinical trial data for tests to secure adoption and reimbursement.

Boehringer backs $20M round in ADC cancer player

Fierce Biotech · article · Nov 3, 2016

NBE Therapeutics raised CHF 20 million ($20.5 million) from investors including PPF Group and Boehringer Ingelheim Venture Fund. The funding will support the development of antibody-drug conjugates (ADCs) targeting multiple myeloma, leukemia, triple-negative breast cancer, and lung cancer.

Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing

Fierce Biotech · article · Jan 7, 2014

Bellicum Pharmaceuticals, Inc. completed a Series B financing, securing an additional $14.7 million, bringing the total raised in the round to $34.4 million. The funding will be used to expand clinical development of Bellicum's lead cellular immunotherapy product candidates.

ARMO BioSciences Closes $30 Million Series B Financing

Fierce Biotech · article · May 29, 2014

ARMO BioSciences, Inc. raised $30 million in a Series B private financing led by NanoDimension. The funds will be used to advance the clinical development of AM0010, an immunotherapy compound for the treatment of solid tumors.

CellCentric raises $220M series D to advance myeloma drug through registration, eyes potential IPO

Fierce Biotech · article · May 6, 2026

CellCentric has raised an oversubscribed $220 million series D financing to advance inobrodib, its first-in-class oral small-molecule inhibitor targeting p300/CBP for the treatment of relapsed or refractory multiple myeloma (RRMM) and other cancers.

Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes

Fierce Biotech · article · Nov 15, 2012

Intarcia Therapeutics announced the completion of two financings totaling $210 million, the largest sum raised by a private biotechnology company in at least 25 years, to fund its global Phase 3 program for ITCA 650 in Type 2 diabetes.

CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients

Fierce Biotech · article · Apr 29, 2015

CRISPR Therapeutics closed a Series A and Series B financing totaling $89 million, including $35 million in Series A and $29 million in Series B, to translate CRISPR-Cas9 gene-editing technology into transformative medicines.

Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing

Fierce Biotech · article · Apr 23, 2015

Jounce Therapeutics completed a $56 million oversubscribed Series B financing. The proceeds will advance its pipeline of cancer immunotherapy programs, including moving its lead program targeting Inducible T cell Co-stimulator (ICOS) into clinical testing.

Pionyr Immunotherapeutics gains meaty $62M series B

Fierce Biotech · article · Dec 13, 2017

Pionyr Immunotherapeutics raised $62 million in a Series B round led by New Enterprise Associates. The funding will support the development of preclinical antibody programs targeting the tumor microenvironment, with two programs nearing IND-enabling studies for solid tumors.

BioNTech's cancer push continues, coughing up $200M for OncoC4's CTLA-4 antibody

Fierce Biotech · article · Mar 20, 2023

BioNTech has announced a licensing deal with OncoC4, taking on the latter’s mid-stage CTLA-4-targeting monoclonal antibody, ONC-392, for $200 million in upfront cash.

BioNTech, Regeneron rack up response rate win for mRNA cancer candidate in phase 2 trial

Fierce Biotech · article · Jul 30, 2024

BioNTech has posted an early win for BNT111, linking a combination of the cancer immunotherapy candidate and Regeneron’s checkpoint inhibitor Libtayo to a better response rate than a historical control in melanoma patients.

Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing

Fierce Biotech · article · Jan 7, 2014

Bellicum Pharmaceuticals secured $34.4 million in a Series B financing to advance its cellular immunotherapy programs for leukemia/lymphoma and prostate cancer, utilizing gene 'switches' to control cell therapies.

Immunocore raises $130M to fund pivotal cancer program

Fierce Biotech · article · Mar 2, 2020

Immunocore raised $130 million in a Series B round to fund pivotal clinical studies of its metastatic uveal melanoma prospect tebentafusp and collaborations with Genentech and GlaxoSmithKline.

Biomarkers are reshaping oncology trial design

Fierce Biotech · article · Apr 20, 2026

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic profiling that enables more precise, patient-centric approaches. In this episode of The Top Line, Allucent’s Dr. Danielly Vicente explores how these advances are improving patient selection, accelerating trial efficiency, and increasing the likelihood of clinical success. From basket and umbrella trials to adaptive designs, biomarker-driven strategies are helping researchers match the right therapies to the right patients faster than ever before.

Cancer immunotherapy works better in the morning, study suggests

STAT · article · Feb 2, 2026

Over the last few years, researchers have noticed that cancer patients who get immunotherapy infusions in the morning seem to do significantly better than those who get treated later. Many scientists, even some who had published such observations, were doubtful that time of day could truly make a big difference. A new randomized trial published Monday in Nature Medicine is drawing renewed attention to the idea that infusing immunotherapy in the morning might be better than the afternoon.

GSK's anti-TIM-3 antibody flunks phase 3 trial as anti-TIGIT failure costs $629M

Fierce Biotech · article · Jul 30, 2025

GSK's cobolimab failed a phase 3 trial in advanced non-small cell lung cancer, leading to a $629 million impairment charge due to the failure of its anti-TIGIT antibody.

Incyte exits immuno-oncology pact, leaving Agenus weighing options for assets

Fierce Biotech · article · Feb 11, 2025

Incyte terminated its immuno-oncology agreement with Agenus, granting Agenus full control over certain assets, which it plans to advance internally or through new partnerships.

Incyte pays MacroGenics $150M for PD-1 inhibitor

Fierce Biotech · article · Oct 25, 2017

Incyte acquired worldwide rights to MacroGenics' PD-1 antibody MGA012 for $150 million upfront, aiming to enhance its oncology pipeline.

Inhibrx’s OX40-Keytruda combo shows promise in early phase 2 data

Fierce Biotech · article · May 11, 2026

Inhibrx's OX40 agonist INBRX-106 combined with Keytruda showed a 44% objective response rate in head and neck cancer patients, doubling the response rate compared to Keytruda alone.

Oncologie reels in $80M to push clinical programs, build pipeline

Fierce Biotech · article · Jun 11, 2019

Oncologie, an immuno-oncology startup, secured $80 million in venture financing to advance three clinical-stage programs, licensing deals, and its biomarker platform. The funds will support key clinical trials, including a proof-of-concept study of bavituximab in combination with Keytruda for stomach cancer. The financing was led by Nan Fung Life Sciences and Pivotal BioVentures China, with participation from Panacea Venture Healthcare and Korea Investment Partners. Oncologie aims to develop its programs in parallel in China and the U.S., leveraging recent regulatory changes in China to expedite drug launches in both markets.

Oncologie kicks off trans-Pacific operations with $16.5M in seed funding

Fierce Biotech · article · Jun 7, 2018

Immuno-oncology startup Oncologie launched operations in Boston and Shanghai after raising $16.5 million in seed funding. Founded by former Eli Lilly VP of oncology Laura Benjamin, the company aims to advance a pipeline of novel, clinical-stage drug candidates through licensing and partnering. Oncologie plans to leverage recent regulatory changes in China to conduct parallel development in both the U.S. and China, potentially shortening the time between launching innovative drugs in these markets.

OncoResponse raises $40M for cancer patient-sourced antibodies

Fierce Biotech · article · Sep 11, 2018

Texas biotech OncoResponse raised $40 million in a Series B financing round to develop drugs based on antibodies from cancer survivors. The funds will advance five programs targeting melanoma, non-small cell lung cancer, prostate cancer, gastric cancer, and chronic myeloid leukemia into human testing. The financing was led by RiverVest Venture Partners, with participation from Qatar Investment Authority and Redmile Group. OncoResponse's I-STAR technology platform, developed in partnership with MD Anderson, uses tissue samples and blood from "elite" disease responders to identify therapeutic leads from the human immune system.

OncoCyte ropes in $7M for cancer diagnostic R&D

Fierce Biotech · article · May 14, 2015

OncoCyte secured $7 million in financing to support the development of its cancer diagnostic tools. The funds will bolster research, clinical development, and commercialization of its PanC-Dx cancer diagnostic tests. The financing includes $3.3 million in cash and $3.3 million in a conversion of existing debt into equity. OncoCyte plans to present final data from its clinical studies in bladder, breast, and lung cancer by the end of 2015. The company continues to collaborate with key research institutions to accelerate the development of its products.

BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed

Bristol Myers Squibb has contracted Hengrui Pharma for an upfront payment of $600 million to advance 13 early-stage oncology programs, potentially totaling over $15 billion.

Follow-up queries

BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed official announcement OR primary sourceBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed latest coverage analysisBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed primary study OR press release OR conference abstractBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed background context Report on major biotech private financings / IPOs and M&A.BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed historical context or prior developmentsBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed competitive context alternative approachesBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed implications analysisBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed caveats criticism open questionsBMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed expert commentarySearch for details on the specific assets involved in the BMS-Hengrui partnership.Investigate any past performance or development timelines of Hengrui's oncology candidates.Look for analyst commentary on the implications of major pharma partnerships with Chinese biotechs.Explore the milestone structures in similar biotech licensing deals to contextualize BMS's agreement with Hengrui.

Likely listener questions

What does this deal mean for the future of oncology drug development?

How might this impact BMS's competitive position in oncology?

What are the potential risks involved in this partnership?

Broader context

Growing trend of Western pharmaceutical companies collaborating with Chinese biotechs.

Rise in interest towards oncology-focused treatments in the global market.

BMS strategically looking to enhance drug development timelines through international partnerships.

Implications

This partnership may accelerate the development of novel oncology therapies.

Investors may view this as a shift towards more strategic Chinese biotech investments.

Potential for re-evaluation of investment strategies in Chinese biotech by VCs focused on oncology.

Open questions

What specific oncology programs are included in the partnership? Which are at what stage?

How will this affect BMS's existing oncology pipeline?

What milestones are detailed that could influence the $15 billion deal value?

How does Hengrui’s R&D capability compare to that of BMS in terms of trial success rates?

Supplemental sources

BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed

Fierce Biotech · article · May 12, 2026

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be worth up to $15.2 billion.

BMS, China's Hengrui Pharma partner to develop 13 drugs

STAT News · article · May 12, 2026

Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs, the latest and a notably large case of a global pharmaceutical company looking to China for its next medicines.

AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

Fierce Biotech · article · Jan 29, 2026

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.

GSK strengthens COPD offering via $12B biobucks Hengrui deal

Fierce Biotech · article · Jul 28, 2025

GSK is paying $500 million upfront to China’s Hengrui Pharma in a deal spanning up to 12 drugs. The companies only name-checked one of these medicines in their July 28 release—a PDE3/4 inhibitor dubbed HRS-9821.

BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence

Fierce Biotech · article · Oct 10, 2025

Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a preclinical CD19 autoimmune program.

GSK strengthens COPD offering via $12B biobucks Hengrui deal

Fierce Biotech · article · Jul 28, 2025

Takeda sets aside $15B for U.S. buys after topsy-turvy R&D week: FT

Fierce Biotech · article · Sep 14, 2016

Takeda has had something of a busy start to September after ditching an option on an early-stage drug development pact with MacroGenics. On Monday it announced it was to essentially allow PRA Health to run much of its clinical ops and even move hundreds of its staff over to the CRO.

Hengrui Soars as GSK Invests in Chinese Drugmaker’s Pipeline

Bloomberg · article · Jul 28, 2025

Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest level in four years after GSK Plc agreed to pay $500 million upfront for a potential treatment for chronic lung disease and lined up options to license other drugs in the Chinese company’s pipeline.

China's rapid rise creates 'heightened risks' for pharma: PwC

Fierce Biotech · article · Jun 18, 2025

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP security, regulatory compliance and strategic alignment.”

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal

Fierce Biotech · article · Mar 5, 2026

Merck KGaA ended its pursuit of an oncology candidate licensed from Jiangsu Hengrui Pharmaceuticals in 2023, opting not to continue development of SW-682, a Hippo pathway inhibitor.

Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025

Fierce Biotech · article · Mar 30, 2026

Kailera Therapeutics plans an IPO to fund its obesity pipeline, including KAI-9531, an injected GLP-1/GIP agonist licensed from Jiangsu Hengrui Pharmaceuticals in 2024.

Treeline reaps $200M series A extension, picks first 3 programs

Fierce Biotech · article · Sep 3, 2025

Treeline Biosciences launched phase 1 lymphoma trials for TLN-121 and TLN-254, the latter licensed from Hengrui Pharmaceuticals in 2023 for $11 million upfront.

China biotechs ‘reshaping’ US biopharma: Jefferies report

Fierce Biotech · article · Jul 14, 2025

Jefferies analysts note that Chinese biotechs are reshaping the U.S. biopharma landscape, with outlicensing deals increasing by 11%. They attribute this to China's advanced scientific capabilities and government support, offering multinational corporations an affordable remedy to pressures like drug pricing and patent expirations.

After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst

Fierce Biotech · article · Feb 24, 2026

Evaluate's Mark Lansdell highlights a 230% increase in average upfront values for licensing deals between Western biopharma companies and Chinese counterparts, indicating that China is no longer a 'bargain basement' for such deals.

Why China Biotech Is Getting Its Own DeepSeek Moment, Too

Bloomberg · article · Jun 10, 2025

Bloomberg's Shuli Ren discusses China's emergence as an attractive destination for Big Pharma's billion-dollar licensing deals, highlighting significant investments by companies like Pfizer and Bristol-Myers Squibb in Chinese biotech firms.

Milestones mitigate risk in biotech deals

Fierce Biotech · article · Jul 21, 2010

Milestone payments are becoming an increasingly familiar aspect of many biotech deals, notes Reuters, as buyers try to mitigate the risks inherent with big purchases.

Targeting the Mitochondrial Transfer Axis in Cancer: From Mechanistic Insights to Therapeutic Rewiring

Mitochondrial transfer between cells plays a crucial role in tumor growth, drug resistance, and immune evasion. By understanding and manipulating these processes, innovative treatments could emerge that enhance therapy outcomes.

Follow-up queries

From Mechanistic Insights to Therapeutic Rewiring official announcement OR primary sourceFrom Mechanistic Insights to Therapeutic Rewiring latest coverage analysisFrom Mechanistic Insights to Therapeutic Rewiring primary study OR press release OR conference abstractFrom Mechanistic Insights to Therapeutic Rewiring background context Covers early-stage research published by PIs at academic institutions, biotech, pharma.From Mechanistic Insights to Therapeutic Rewiring historical context or prior developmentsFrom Mechanistic Insights to Therapeutic Rewiring competitive context alternative approachesFrom Mechanistic Insights to Therapeutic Rewiring implications analysisFrom Mechanistic Insights to Therapeutic Rewiring caveats criticism open questionsFrom Mechanistic Insights to Therapeutic Rewiring expert commentaryFrom Mechanistic Insights to Therapeutic Rewiring corresponding author affiliationFrom Mechanistic Insights to Therapeutic Rewiring author information affiliationsSearch for recent preclinical trials addressing mitochondrial transfer targeting in cancer.Look for detailed reviews or studies on the role of Miro1 in various tissues apart from tumors.Investigate which cancers are most commonly associated with mitochondrial transfer mechanisms as outlined in recent publications.Search for clinical trial registries that include studies on therapies targeting mitochondrial transfer dynamics.

Likely listener questions

What are the most promising therapeutic targets within the mitochondrial transfer pathway?

How can early-stage biotech companies position themselves within this emerging field?

What are the main challenges faced when translating these findings into clinical practice?

Broader context

Mitochondrial dynamics are linked to critical oncological processes including tumor growth and therapeutic resistance.

Recent studies explore the interaction between metabolic pathways and immune evasion, signaling the importance of metabolic reprogramming in cancer.

Implications

Targeting mitochondrial dynamics could lead to innovative treatment strategies that disrupt tumor metabolism.

The approach may enhance overall therapeutic efficacy against resistant cancer phenotypes, attracting funding and interest from investors.

Open questions

What preclinical studies demonstrate the initial efficacy of targeting mitochondrial transfer in specific cancer types?

How do specific proteins involved in mitochondrial dynamics affect treatment in adjacent non-cancerous tissues, and what unintended consequences could arise?

Which cancer types exhibit a dependency on mitochondrial transfer, making them prime candidates for targeted therapies?

What are the optimal clinical trial designs to validate these therapeutic approaches in a clinical setting?

How do these findings align with other emerging cancer therapies, particularly concerning potential synergies?

Supplemental sources

Mechanistic insights into chromatin targeting by leukemic NUP98-PHF23 fusion

Nature Communications · scientific_publication · Jul 3, 2020

This study provides mechanistic insights into chromatin targeting by the leukemic NUP98-PHF23 fusion protein, highlighting its role in acute myeloid leukemia and potential therapeutic implications.

Tackling cuproptosis: from metabolic rewiring to therapeutic exploitation in cancer

Cellular & Molecular Immunology · scientific_publication · Jan 27, 2026

This article discusses the concept of cuproptosis, its role in metabolic rewiring in cancer, and potential therapeutic strategies targeting this process.

Enhancer rewiring in tumors: an opportunity for therapeutic intervention

Oncogene · scientific_publication · May 1, 2021

This review explores how enhancer rewiring in tumors can be targeted for therapeutic intervention, discussing mechanisms and potential drug development strategies.

Exosomes in depression: mechanistic insights, diagnostic potential, and therapeutic opportunities

Molecular Psychiatry · scientific_publication · Apr 28, 2026

This review examines the role of exosomes in depression, providing mechanistic insights and discussing their potential as diagnostic and therapeutic targets.

Investigating C7 modified tetrandrine derivatives for synthesis anti-hepatocellular carcinoma activity and mechanistic insights

Scientific Reports · scientific_publication · Sep 29, 2025

This study investigates the synthesis of C7 modified tetrandrine derivatives and their anti-hepatocellular carcinoma activity, providing mechanistic insights into their therapeutic potential.

PTH receptor-1 signalling—mechanistic insights and therapeutic prospects

Nature Reviews Endocrinology · scientific_publication · Aug 25, 2015

This review discusses the mechanisms of PTHR1 signaling and how these insights can inform treatments for hypoparathyroidism and osteoporosis.

Cellular rewiring in lethal prostate cancer: the architect of drug resistance

Nature Reviews Urology · scientific_publication · Mar 16, 2020

This review examines how prostate cancer cells adapt to therapies through cellular rewiring, leading to drug resistance, and suggests new therapeutic strategies.

Endocrine-metabolic crosstalk in erectile dysfunction: mechanistic insights and therapeutic implications

International Journal of Impotence Research · scientific_publication · May 12, 2026

This article discusses the interplay between endocrine and metabolic factors in erectile dysfunction and explores potential therapeutic approaches.

From Mechanistic Insights to Therapeutic Rewiring: Targeting the PI3K/AKT/mTOR Pathway in Cancer

Nature · scientific_publication · Nov 6, 2019

This study provides a comprehensive overview of the PI3K/AKT/mTOR pathway's role in cancer and discusses therapeutic strategies targeting this pathway.

From Mechanistic Insights to Therapeutic Rewiring: Targeting the Wnt/β-Catenin Pathway in Cancer

Nature · scientific_publication · Nov 6, 2019

This research explores the Wnt/β-Catenin pathway's involvement in cancer and presents potential therapeutic approaches for targeting this pathway.

From Mechanistic Insights to Therapeutic Rewiring: Targeting the MAPK Pathway in Cancer

Nature · scientific_publication · Nov 6, 2019

This article examines the MAPK pathway's contribution to cancer progression and discusses therapeutic strategies aimed at this pathway.

From Mechanistic Insights to Therapeutic Rewiring: Targeting the Notch Pathway in Cancer

Nature · scientific_publication · Nov 6, 2019

This paper investigates the Notch pathway's role in cancer and evaluates potential therapeutic interventions targeting this pathway.

From Mechanistic Insights to Therapeutic Rewiring: Targeting the Hedgehog Pathway in Cancer

Nature · scientific_publication · Nov 6, 2019

This study delves into the Hedgehog pathway's involvement in cancer and discusses therapeutic strategies for targeting this pathway.

Remyelination in the CNS: from biology to therapy

Nature Reviews Neuroscience · scientific_publication · Nov 1, 2008

This 2008 review discusses the mechanisms of remyelination in the central nervous system and explores therapeutic strategies to enhance this process.

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy

Signal Transduction and Targeted Therapy · scientific_publication · Jul 9, 2021

This 2021 article provides a historical overview of DNA damage repair mechanisms and their clinical applications in cancer therapy.

Regenerating CNS myelin — from mechanisms to experimental medicines

Nature Reviews Neuroscience · scientific_publication · Nov 16, 2017

This 2017 article explores the mechanisms of central nervous system myelin regeneration and discusses experimental treatments.

From monoamines to genomic targets: a paradigm shift for drug discovery in depression

Nature Reviews Drug Discovery · scientific_publication · Feb 1, 2004

This 2004 review discusses the evolution of antidepressant drug discovery, highlighting the shift from monoamine-based therapies to genomic targets.

Biased signalling: from simple switches to allosteric microprocessors

Nature Reviews Drug Discovery · scientific_publication · Jan 5, 2018

This article explores the concept of biased signalling in G protein-coupled receptors and its implications for drug discovery.

Emerging role of tumor cell plasticity in modifying therapeutic response

Signal Transduction and Targeted Therapy · scientific_publication · Oct 7, 2020

This article discusses how tumor cell plasticity influences therapeutic responses and resistance mechanisms.

Non-genetic mechanisms of therapeutic resistance in cancer

Nature Reviews Cancer · scientific_publication · Oct 8, 2020

This perspective highlights non-genetic mechanisms underlying therapeutic resistance in cancer.

Pharmacological targeting of oncogenic condensates in cancer: mechanistic insights and therapeutic opportunities

Acta Pharmacologica Sinica · scientific_publication · Mar 4, 2026

This review discusses the role of oncogenic condensates in cancer, their formation through liquid–liquid phase separation, and potential therapeutic strategies targeting these condensates.

The hippocampus as a central hub in ketamine’s antidepressant action: from molecules to circuit rewiring

Neuropsychopharmacology · scientific_publication · Nov 26, 2025

This article examines how ketamine enhances hippocampal synaptic plasticity and its role in antidepressant effects, focusing on molecular and circuit-level mechanisms.

Non-coding RNAs in disease: from mechanisms to therapeutics

Nature Reviews Genetics · scientific_publication · Nov 15, 2023

This review summarizes the roles of non-coding RNAs in various diseases and discusses their potential as biomarkers and therapeutic targets.

Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications

Experimental & Molecular Medicine · scientific_publication · Mar 3, 2025

This article explores metabolic alterations in hepatocellular carcinoma and their roles in disease progression, highlighting potential therapeutic approaches targeting these pathways.

Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies

Cell Death Discovery · scientific_publication · Feb 11, 2026

This study investigates the role of mitophagy in pancreatic cancer and discusses potential therapeutic strategies targeting this process.

Therapeutic mechanisms of psychedelics and entactogens

Neuropsychopharmacology · scientific_publication · Jul 24, 2023

This article explores how psychedelics and entactogens produce rapid and sustained therapeutic effects across various mental health conditions. It discusses the modulation of neural circuits and the importance of understanding these mechanisms for developing effective treatments.

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

Nature Medicine · scientific_publication · Mar 3, 2016

This perspective discusses how stress and rapid-acting antidepressants affect synaptic plasticity in depression. It highlights the role of neuronal function and morphology in mood regulation and cognitive function, emphasizing the need for treatments that rapidly reverse synaptic deficits caused by stress.

Targeting metaplasticity mechanisms to promote sustained antidepressant actions

Molecular Psychiatry · scientific_publication · Jan 4, 2024

This article reviews how rapid-acting antidepressants like ketamine induce metaplasticity, a process that regulates future synaptic plasticity. It suggests that targeting metaplasticity mechanisms could lead to sustained antidepressant effects and discusses potential therapeutic strategies.

Nerve-to-cancer transfer of mitochondria during cancer metastasis

Nature · scientific_publication · Jun 25, 2025

This study demonstrates that cancer-associated neurons enhance cancer cell metabolic capacity and metastatic dissemination by transferring mitochondria to cancer cells.

Immune evasion through mitochondrial transfer in the tumour microenvironment

Nature · scientific_publication · Jan 22, 2025

This research identifies mitochondrial transfer from cancer cells to tumor-infiltrating lymphocytes (TILs) as a mechanism of immune evasion, leading to mitochondrial dysfunction and impaired T-cell function.

Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy

Cell · article · Nov 14, 2024

This study shows that intercellular nanotube-mediated mitochondrial transfer from bone marrow stromal cells to T cells enhances T cell metabolic fitness and antitumor efficacy.

Mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells promoting TGFβ1-mediated tumor progression

Nature Communications · scientific_publication · Apr 30, 2024

This research demonstrates that mitochondrial genome transfer from cancer cells to adjacent colonic epithelial cells drives metabolic reprogramming, promoting TGFβ1-mediated tumor progression.

Methodological validation of Miro1 retention as a candidate Parkinson’s disease biomarker

npj Parkinson's Disease · scientific_publication · Sep 1, 2025

This study validates Miro1 retention as a potential biomarker for Parkinson's disease by quantifying Miro1 levels in various cell types and correlating retention scores with clinical data.

MIRO1 mutation leads to metabolic maladaptation resulting in Parkinson’s disease-associated dopaminergic neuron loss

npj Systems Biology and Applications · scientific_publication · Apr 1, 2026

Research indicates that mutations in MIRO1 cause metabolic maladaptation, leading to the loss of dopaminergic neurons associated with Parkinson's disease.

A guide to studying mitochondria transfer

Nature Cell Biology · scientific_publication · Oct 18, 2023

This article provides a comprehensive overview of mitochondrial transfer mechanisms, discussing their roles in various physiological and pathological contexts, including cancer.

Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic

Nature Cancer · scientific_publication · Aug 28, 2025

This study demonstrates that mitochondrial transfer from cancer cells to fibroblasts reprograms the fibroblasts, enhancing their pro-tumorigenic properties.

The power and potential of mitochondria transfer

Nature · scientific_publication · Nov 8, 2023

This review discusses the mechanisms of intercellular mitochondrial transfer and its implications in various diseases, including cancer.

Mitochondrial swap from cancer to immune cells thwarts anti-tumour defences

Nature · scientific_publication · Jan 22, 2025

This article highlights how cancer cells transfer mitochondria to immune cells, impairing their anti-tumor functions.

ClinicalTrials.gov: Mitochondrial Transfer Dynamics Therapies

ClinicalTrials.gov · government · Unknown

A search on ClinicalTrials.gov for studies related to therapies targeting mitochondrial transfer dynamics yields several ongoing and completed trials.

Coverage memory updates

Biotech financings and M&A

mediumrepeat after 2 months

The $122 million raise by CREATE Medicines represents a significant development in innovative oncology financing, indicating strong investor confidence in the sector.

Preclinical research

narrowrepeat after 2 months

This study's implications for personalized cancer therapies offer actionable insights but should not be repeated soon to avoid redundancy.

Preclinical research

narrowrepeat after 2 months

Discussing novel biomarkers for pancreatic cancer's early detection holds substantial future potential, and should not be revisited soon.

Biotech financings and M&A

mediumrepeat after 2 months

OncoTech's $20 million raise marks a notable investment trend in immunotherapy and should be monitored for ongoing developments.

Biotech financings and M&A

mediumrepeat after 2 months

The partnership between BMS and Hengrui Pharma showcases a broader trend of collaboration boosting oncology drug development efforts, meriting ongoing observation.

Preclinical research

narrowrepeat after 2 months

Insights into mitochondrial dynamics offer novel therapeutic avenues but should not be repeated frequently due to specificity.

Reporter outputs

Research trace

Biotech financings and M&A

Report on major biotech private financings / IPOs and M&A.

last week

Search queries

recent biotech financing oncology deals over $10M May 2026biotech acquisitions over $200M May 2026oncology partnerships with strategic relevance May 2026latest IPOs in biotech with a focus on oncology May 2026venture capital funding biotech oncology over $30M May 2026recent preclinical oncology research announcements May 2026latest biotech funding rounds May 2026M&A activity in biotechnology sector May 2026

Editor assignments

Planned 4m 30s

Emphasize the innovative aspects of in vivo CAR-T therapies and their potential implications for the oncology market. Discuss investor motivations and expectations.

Planned 4m 30s

Explore the broader implications of this funding for the immunotherapy landscape and the strategic importance of cancer immunotherapy solutions.

Planned 4m 30s

Explain the development directly, supply enough background to orient an experienced listener, and focus on what materially changed.

Candidate stories

BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed

Bristol Myers Squibb partnered with Hengrui Pharma, paying $600 million upfront for 13 early-stage programs, with the potential for the deal to be worth over $15 billion.

This substantial partnership could impact the oncology landscape by providing access to Hengrui's innovative pipeline and leveraging China's rapid R&D capabilities, which may lead to accelerated drug development timelines.

Relevance 9.5/10 · Novelty 8.5/10 · Confidence 9/10

CREATE Medicines raises $122 million for in vivo CAR-T therapies

CREATE Medicines has secured $122 million in funding to advance its in vivo CAR-T therapies, a promising modality in oncology treatment.

The funding will support innovative approaches in CAR-T therapy, potentially expanding treatment options for cancer patients and indicating strong investor confidence in advanced oncology therapies.

Relevance 9.1/10 · Novelty 8/10 · Confidence 8.8/10

OncoTech Raises $20M in Series B Funding for Cancer Immunotherapy

OncoTech has raised $20 million in a Series B round to boost its clinical trials aimed at advancing cancer immunotherapy solutions.

The fundraising attracts attention in the oncology sector as immunotherapy continues to be a pivotal area of therapeutic development, presenting potential for substantial market impact.

Relevance 8.5/10 · Novelty 7.5/10 · Confidence 8/10

Deep research

CREATE Medicines raises $122 million for in vivo CAR-T therapies

Angle: CREATE Medicines' recent $122 million Series B funding underscores increasing investor confidence in in vivo CAR-T therapies, emphasizing their relevance in the oncology landscape.

CREATE Medicines has secured $122 million in Series B funding to advance its in vivo CAR-T therapies, signifying investor support for innovative oncology solutions.

Emerging trends in CAR-T therapy development

Investor confidence in advanced oncology treatments

Competition within the in vivo CAR-T market

What makes in vivo CAR-T therapies distinct from traditional methods?

How do the investments reflect broader market trends in oncology?

What potential challenges could CREATE encounter in clinical trials?

Investor confidence suggests a shift toward innovative CAR-T therapies

Potential to redefine treatment methodologies in oncology

If successful, could establish new treatment guidelines for CAR-T therapies

Full research memo

# PRIMARY ANGLE CREATE Medicines' recent $122 million Series B funding underscores increasing investor confidence in in vivo CAR-T therapies, emphasizing their relevance in the oncology landscape. This investment will support CREATE's development of innovative CAR-T solutions, potentially reshaping treatment methodologies and market dynamics within this space. # WHY THIS STORY IS WORTH AIRTIME The funding round led by prominent investors such as Newpath Partners and ARCH Venture Partners illustrates a significant endorsement for CREATE's approach to in vivo CAR-T therapies, a modality that aims to simplify T-cell therapy production and administration. This development aligns with a broader trend where venture capital is flowing into innovative oncology treatments, signaling potential shifts in prioritization within investor portfolios. # BACKGROUND AND CONTEXT In vivo CAR-T cell therapies offer the promise of overcoming limitations associated with traditional ex vivo methods, such as complex manufacturing and logistical challenges. Companies like CREATE Medicines are pioneering this approach, which is particularly attractive given the success of existing CAR-T treatments in hematological malignancies. However, integrating such therapies for broader oncological applications remains complex and fraught with regulatory hurdles. The last major developments in the CAR-T modality include acquisitions and funding rounds from several industry leaders, highlighting the competitive landscape's intensity. The field is marked by significant investments, as seen with Eli Lilly’s $2.4 billion acquisition of Orna, which strengthens its position in in vivo therapeutic development. # WHAT IS NEW The $122 million funding announced on May 14, 2026, is a substantial boost for CREATE, allowing them to accelerate the clinical development of their in vivo CAR-T candidates. Unlike traditional CAR-T therapies that require patient-derived cells to be modified and reintroduced, CREATE's approach aims to generate CAR-T cells within the patient's body, which could provide logistical and therapeutic advantages. # KEY EVIDENCE - **Amount Raised**: $122 million secured in Series B funding. - **Investors**: Led by Newpath Partners and ARCH Venture Partners, indicating strong support from established venture capital. - **Therapeutic Focus**: CREATE's in vivo CAR-T therapies target both autoimmune diseases and cancer, suggesting a dual approach which may maximize market potential. Statements from investors underscore a belief in the transformative potential of CREATE's technology, indicating that in vivo approaches could reduce costs and improve patient outcomes compared to prior CAR-T methods. # TECHNICAL OR DOMAIN EXPLANATION In vivo CAR-T therapies involve engineering T-cells to express a chimeric antigen receptor (CAR) directly within the patient’s body. This method eliminates the cumbersome logistics of cell extraction, manipulation, and re-infusion. Key barriers include efficient vector delivery and ensuring sustained CAR expression, which CREATE aims to address. Successful execution of this strategy could enable a new era of widespread CAR-T applications in oncology. # PEOPLE, INSTITUTIONS, AND OTHER REQUIRED DETAILS - **CREATE Medicines**: Previously known as Myeloid Therapeutics, the company is focused on advancing in vivo CAR-T innovation. - **Established Investors**: Newpath Partners and ARCH Venture Partners, known for backing groundbreaking biotechnological advancements. No specific details on the individual therapies in the pipeline have been disclosed at this stage. # IMPLICATIONS The infusion of capital into CREATE Medicines signifies broader trends toward investing in less conventional CAR-T therapies, which may recalibrate market focus on therapies that promise greater convenience and efficiency. If CREATE's in vivo models prove effective, they could redefine treatment guidelines and challenge existing paradigms in cancer treatment. Analyst responses have generally been positive, indicating optimism surrounding the potential impact on patient care and market demand. # OPEN QUESTIONS AND CAVEATS - What specific in vivo CAR-T candidates are currently under development, and what are their respective timelines for clinical trials? - How does CREATE compare to competitors in terms of therapeutic efficacy and safety profiles? - What are the anticipated regulatory challenges that CREATE might face in bringing its therapies to market? - With the funding announced, how will CREATE balance development costs and market potential? The specifics about CREATE's lead assets and the anticipated timelines for trials remain unclear and warrant closer scrutiny as the company progresses. # WRITING GUIDANCE The writing should maintain a focus on the investment trends in oncology therapeutics, emphasizing CREATE's strategic positioning in the market. Make the narrative compelling by linking investor optimism with emerging scientific advancements, framing CREATE’s story within the broader context of CAR-T therapy evolution. Engage the audience by addressing potential investor concerns and speculating on future market implications as the field evolves.

OncoTech Raises $20M in Series B Funding for Cancer Immunotherapy

Angle: OncoTech's recent $20 million Series B funding marks a pivotal moment in the oncology landscape, particularly for novel immunotherapy approaches.